Eli Lilly Tumbles On Lowered Guidance

Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Balanced Outlook with Long-Term Optimism: Steve Scala Maintains Buy Rating for Eli Lilly & Co
TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00.Stay ...
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Eli Lilly CEO David Ricks: Projecting 32% total growth for company in 2025
Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the ...
TD Cowen Sticks to Its Buy Rating for Eli Lilly & Co (LLY)
TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00. The ...
FiercePharma1d
JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
BioPharma Dive1d
Lilly blames slower-than-expected growth for 2024 sales miss
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...
As Lilly Stock Tumble on GLP-1 Demand Worries, CEO Says All Is Well
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.